TY - JOUR
TI - Comparative study of serum and synovial fluid interleukin-11 levels in
patients with various arthritides
AU - Trontzas, P
AU - Kamper, EF
AU - Potamianou, A
AU - Kyriazis, NC and
AU - Kritikos, H
AU - Stavridis, J
JO - Clinical Biochemistry
PY - 1998
VL - 31
TODO - 8
SP - 673-679
PB - PERGAMON-ELSEVIER SCIENCE LTD
SN - 0009-9120
TODO - 10.1016/S0009-9120(98)00062-9
TODO - interleukin-11; serum; synovial fluid; rheumatoid arthritis;
seronegative spondyloarthritis; gout; osteoarthritis; acute phase
response
TODO - Objective: To determine the levels of serum and synovial fluid (SF)
interleukin (IL)-11 in patients with various arthritides and estimate
the contribution of IL-11 to acute phase response (APR).
Design and methods: Serum and SF IL-11 were measured by ELISA in
patients with rheumatoid arthritis (RA, n = 31), seronegative
spondyloarthritis (SSA, n = 23), gout (GT, n = 14) and osteoarthritis
(OA, n = 20) and were correlated with ESR and acute phase proteins as
well as with cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF alpha.
Results: IL-11 was detected in both serum and SF in each group, with
IL-11 being statistically higher in SF than serum in all groups,
suggesting reduced catabolism or increased synthesis of IL-11
intra-articularly. Median SF IL-11 levels were higher in OA patients
than in other groups and in the treated than in the untreated RA
subgroup. Moreover, serum and SF IL-11 were correlated significantly
with each other, and moderately with the other cytokines examined in RA,
SSA, and GT, but not in OA patients, while a significant negative
correlation was found with a few of the inflammatory markers examined in
each group.
Conclusions: Our findings provide evidence of extensive intraarticular
expression of IL-11 in arthritides, especially in CA and treated RA
patients, suggesting a protective role for IL-11 in joints, probably
through the induction of tissue inhibitor of metalloproteinases. (C)
1998 The Canadian Society of Clinical Chemists .
ER -